{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T19:12:19Z","timestamp":1772910739489,"version":"3.50.1"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2006,3,1]]},"DOI":"10.1038\/nrc1815","type":"journal-article","created":{"date-parts":[[2006,2,24]],"date-time":"2006-02-24T09:54:44Z","timestamp":1140774884000},"page":"204-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":274,"title":["Vaccines for tumour prevention"],"prefix":"10.1038","volume":"6","author":[{"given":"Pier-Luigi","family":"Lollini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Forni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl.","key":"BFnrc1815_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1038\/nm1209","volume":"11","author":"SA Plotkin","year":"2005","unstructured":"Plotkin, S. A. Vaccines: past, present and future. Nature Med. 11 (Suppl.), S5\u2013S11 (2005).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR2","unstructured":"World Cancer Report (eds Stewart, B. W. & Kleihues, P. ) (IARC Press, Lyon, 2003)."},{"key":"BFnrc1815_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2005.05.132","volume":"23","author":"BW Stewart","year":"2005","unstructured":"Stewart, B. W. & Coates, A. S. Cancer prevention: a global perspective. J. Clin. Oncol. 23, 392\u2013403 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1815_CR4","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1001\/jama.284.23.3040","volume":"284","author":"MH Chang","year":"2000","unstructured":"Chang, M. H. et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 284, 3040\u20133042 (2000).","journal-title":"JAMA"},{"key":"BFnrc1815_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","volume":"6","author":"LL Villa","year":"2005","unstructured":"Villa, L. L. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6, 271\u2013278 (2005).","journal-title":"Lancet Oncol."},{"key":"BFnrc1815_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nrc1757","volume":"5","author":"P Goymer","year":"2005","unstructured":"Goymer, P. Gardasil \u2014 the perfect guard? Nature Rev. Cancer 5, 840 (2005).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1815_CR7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1158\/1055-9965.EPI-04-0157","volume":"14","author":"GA Colditz","year":"2005","unstructured":"Colditz, G. A. Epidemiology and prevention of breast cancer. Cancer Epidemiol. Biomarkers Prev. 14, 768\u2013772 (2005).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrc1815_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc844","volume":"2","author":"MB Sporn","year":"2002","unstructured":"Sporn, M. B. & Suh, N. Chemoprevention: an essential approach to controlling cancer. Nature Rev. Cancer 2, 537\u2013543 (2002).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1815_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick, J. et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296\u2013300 (2003).","journal-title":"Lancet"},{"key":"BFnrc1815_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.coi.2004.01.003","volume":"16","author":"S Ostrand-Rosenberg","year":"2004","unstructured":"Ostrand-Rosenberg, S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol. 16, 143\u2013150 (2004).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrc1815_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nri1150","volume":"3","author":"OJ Finn","year":"2003","unstructured":"Finn, O. J. Cancer vaccines: between the idea and the reality. Nature Rev. Immunol. 3, 630\u2013641 (2003).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrc1815_CR12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909\u2013915 (2004).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00262-003-0423-6","volume":"52","author":"E Mihich","year":"2003","unstructured":"Mihich, E. Cellular immunity for cancer chemoimmunotherapy \u2014 an overview. Cancer Immunol. Immunother. 52, 661\u2013662 (2003).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrc1815_CR14","first-page":"5895","volume":"63","author":"C Cuadros","year":"2003","unstructured":"Cuadros, C. et al. Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2\/neu mice. Cancer Res. 63, 5895\u20135901 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR15","first-page":"5067","volume":"53","author":"F Cavallo","year":"1993","unstructured":"Cavallo, F. et al. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary denocarcinoma. Cancer Res. 53, 5067\u20135070 (1993).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR16","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jnci\/89.14.1049","volume":"89","author":"F Cavallo","year":"1997","unstructured":"Cavallo, F. et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl Cancer Inst. 89, 1049\u20131058 (1997).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1815_CR17","first-page":"6022","volume":"54","author":"A Allione","year":"1994","unstructured":"Allione, A. et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor \u03b1, granulocyte\u2013macrophage colony-stimulating factor, and \u03b3-interferon gene or admixed with conventional adjuvants. Cancer Res. 54, 6022\u20136026 (1994).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm0598-594","volume":"4","author":"L Zitvogel","year":"1998","unstructured":"Zitvogel, L. et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med. 4, 594\u2013600 (1998).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719\u2013726 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1815_CR20","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney, D. G. et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15, 3266\u20133274 (1997).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1815_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm0398-270","volume":"4","author":"AN Houghton","year":"1998","unstructured":"Houghton, A. N. & Lloyd, K. O. Stuck in the MUC on the long and winding road. Nature Med. 4, 270\u2013271 (1998).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR22","doi-asserted-by":"publisher","first-page":"11798","DOI":"10.1073\/pnas.93.21.11798","volume":"93","author":"Y Noguchi","year":"1996","unstructured":"Noguchi, Y., Jungbluth, A., Richards, E. C. & Old, L. J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl Acad. Sci. USA 93, 11798\u201311801 (1996). Shows that IL-12-mediated stimulation of the immune response effectively counteracts chemical carcinogenesis.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1815_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc1565","volume":"5","author":"JE Green","year":"2005","unstructured":"Green, J. E. & Hudson, T. The promise of genetically engineered mice for cancer prevention studies. Nature Rev. Cancer 5, 184\u2013198 (2005).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1815_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nm0705-715","volume":"11","author":"DL Woodland","year":"2005","unstructured":"Woodland, D. L. & Blackman, M. A. Vaccine development: baring the 'dirty little secret'. Nature Med. 11, 715\u2013716 (2005).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/sj.gt.3301416","volume":"8","author":"S Rovero","year":"2001","unstructured":"Rovero, S. et al. Insertion of the DNA for the 163\u2013171 peptide of IL1\u03b2 enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2\/neu transgenic BALB\/c mice. Gene Ther. 8, 447\u2013452 (2001).","journal-title":"Gene Ther."},{"key":"BFnrc1815_CR26","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1078-0432.CCR-04-1873","volume":"11","author":"M Spadaro","year":"2005","unstructured":"Spadaro, M. et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neo-adjuvant IL-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11, 1941\u20131952 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1815_CR27","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1084\/jem.194.9.1195","volume":"194","author":"P Nanni","year":"2001","unstructured":"Nanni, P. et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2\/neu transgenic mice. J. Exp. Med. 194, 1195\u20131205 (2001). Shows that rat Erbb2 -transgenic mice vaccinated with a combination of ERBB2 antigen, allogeneic MHC molecules and IL-12 show complete and sustained prevention of mammary carcinogenesis and that the protective mechanisms are based on IFN\u03b3 and antibodies.","journal-title":"J. Exp. Med."},{"key":"BFnrc1815_CR28","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-03-2984","volume":"64","author":"C De Giovanni","year":"2004","unstructured":"De Giovanni, C. et al. Immunoprevention of HER-2\/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res. 64, 4001\u20134009 (2004).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1172\/JCI19850","volume":"113","author":"E Quaglino","year":"2004","unstructured":"Quaglino, E. et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2\/neu preneoplastic lesions. J. Clin. Invest 113, 709\u2013717 (2004).","journal-title":"J. Clin. Invest"},{"key":"BFnrc1815_CR30","first-page":"2518","volume":"63","author":"P Cappello","year":"2003","unstructured":"Cappello, P. et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2\/neu transgenic BALB\/c mice. Cancer Res. 63, 2518\u20132525 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR31","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1073\/pnas.91.9.3916","volume":"91","author":"X Ye","year":"1994","unstructured":"Ye, X., McCarrick, J., Jewett, L. & Knowles, B. B. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl Acad. Sci. USA 91, 3916\u20133920 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1815_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00262-003-0483-7","volume":"53","author":"M Spadaro","year":"2004","unstructured":"Spadaro, M. et al. Immunological inhibition of carcinogenesis. Cancer Immunol. Immunother. 53, 204\u2013216 (2004).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrc1815_CR33","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0002-9440(10)62339-5","volume":"166","author":"A Astolfi","year":"2005","unstructured":"Astolfi, A. et al. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2\/neu-positive basal-like mammary carcinoma. Am. J. Pathol. 166, 1205\u20131216 (2005).","journal-title":"Am. J. Pathol."},{"key":"BFnrc1815_CR34","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1158\/0008-5472.CAN-04-2341","volume":"64","author":"S Croci","year":"2004","unstructured":"Croci, S. et al. Immunological prevention of a multigene cancer syndrome. Cancer Res. 64, 8428\u20138434 (2004).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR35","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1084\/jem.20031190","volume":"199","author":"A Vogt","year":"2004","unstructured":"Vogt, A. et al. Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein. J. Exp. Med. 199, 753\u2013761 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnrc1815_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nature03954","volume":"437","author":"G Willimsky","year":"2005","unstructured":"Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumors avoid destruction by inducing T cell tolerance. Nature 437, 141\u2013146 (2005).","journal-title":"Nature"},{"key":"BFnrc1815_CR37","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1200\/JCO.2005.11.005","volume":"23","author":"CJ Fabian","year":"2005","unstructured":"Fabian, C. J. & Kimler, B. F. Selective estrogen-receptor modulators for primary prevention of breast cancer. J. Clin. Oncol. 23, 1644\u20131655 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1815_CR38","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1200\/JCO.2005.11.027","volume":"23","author":"J Cuzick","year":"2005","unstructured":"Cuzick, J. Aromatase inhibitors for breast cancer prevention. J. Clin. Oncol. 23, 1636\u20131643 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1815_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nri1550","volume":"5","author":"R Antia","year":"2005","unstructured":"Antia, R., Ganusov, V. V. & Ahmed, R. The role of models in understanding CD8+ T-cell memory. Nature Rev. Immunol. 5, 101\u2013111 (2005).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrc1815_CR40","first-page":"880","volume":"61","author":"RT Reilly","year":"2001","unstructured":"Reilly, R. T. et al. The collaboration of both humoral and cellular HER-2\/neu-targeted immune responses is required for the complete eradication of HER-2\/neu-expressing tumors. Cancer Res. 61, 880\u2013883 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR41","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1084\/jem.20042167","volume":"201","author":"AM Ercolini","year":"2005","unstructured":"Ercolini, A. M. et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J. Exp. Med. 201, 1591\u20131602 (2005). Shows that ERBB2-expanded CD4+ CD25+ T reg cells are a significant barrier for the vaccine-mediated activation of high-avidity, ERBB2-specific CD8+ T cells. The fact that the immune response to ERBB2 vaccine is dampened by T reg cells offers the prospect of increasing the effects of vaccination by using treatments that are aimed at inhibiting T reg cells.","journal-title":"J. Exp. Med."},{"key":"BFnrc1815_CR42","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1158\/0008-5472.CAN-03-2962","volume":"64","author":"E Quaglino","year":"2004","unstructured":"Quaglino, E. et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2\/neu transgenic mice. Cancer Res. 64, 2858\u20132864 (2004).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR43","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/eji.200324427","volume":"34","author":"J Lustgarten","year":"2004","unstructured":"Lustgarten, J., Dominguez, A. L. & Cuadros, C. The CD8+ T cell repertoire against Her-2\/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34, 752\u2013761 (2004). Because of tolerance, the CD8+ T-cell response in rat Erbb2 -transgenic mice is of low avidity. However, these low-avidity cells are able to carry out a significant anti-ERBB2 immune response.","journal-title":"Eur. J. Immunol."},{"key":"BFnrc1815_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/BD-2004-20105","volume":"20","author":"T Pannellini","year":"2004","unstructured":"Pannellini, T., Forni, G. & Musiani, P. Immunobiology of her-2\/neu transgenic mice. Breast Dis. 20, 33\u201342 (2004).","journal-title":"Breast Dis."},{"key":"BFnrc1815_CR45","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.4049\/jimmunol.165.9.5133","volume":"165","author":"S Rovero","year":"2000","unstructured":"Rovero, S. et al. DNA vaccination against rat her-2\/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB\/c mice. J. Immunol. 165, 5133\u20135142 (2000).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR46","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4049\/jimmunol.159.3.1336","volume":"159","author":"Y Nagata","year":"1997","unstructured":"Nagata, Y. et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2\/HER2\/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159, 1336\u20131343 (1997).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR47","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.4049\/jimmunol.174.7.4228","volume":"174","author":"JM Park","year":"2005","unstructured":"Park, J. M. et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174, 4228\u20134236 (2005).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR48","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-03-3442","volume":"64","author":"Y Sakai","year":"2004","unstructured":"Sakai, Y. et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64, 8022\u20138028 (2004).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR49","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nm0795-644","volume":"1","author":"M Katsumata","year":"1995","unstructured":"Katsumata, M. et al. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nature Med. 1, 644\u2013648 (1995).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR50","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.4049\/jimmunol.173.4.2288","volume":"173","author":"P Nanni","year":"2004","unstructured":"Nanni, P. et al. Immunoprevention of mammary carcinoma in HER-2\/neu transgenic mice is IFN-\u03b3 and B cell dependent. J. Immunol. 173, 2288\u20132296 (2004).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR51","first-page":"5812","volume":"58","author":"M Rodolfo","year":"1998","unstructured":"Rodolfo, M. et al. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. Cancer Res. 58, 5812\u20135817 (1998).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR52","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1126\/science.1113401","volume":"309","author":"G Peng","year":"2005","unstructured":"Peng, G. et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309, 1380\u20131384 (2005).","journal-title":"Science"},{"key":"BFnrc1815_CR53","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nm0904-900","volume":"10","author":"EM Shevach","year":"2004","unstructured":"Shevach, E. M. Fatal attraction: tumors beckon regulatory T cells. Nature Med. 10, 900\u2013901 (2004).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR54","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ni1178","volume":"6","author":"S Sakaguchi","year":"2005","unstructured":"Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunol. 6, 345\u2013352 (2005).","journal-title":"Nature Immunol."},{"key":"BFnrc1815_CR55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1074-7613(00)00026-1","volume":"13","author":"HL Hanson","year":"2000","unstructured":"Hanson, H. L. et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 13, 265\u2013276 (2000).","journal-title":"Immunity."},{"key":"BFnrc1815_CR56","unstructured":"Mechanisms of Tumor Escape From The Immune Response (ed. Ochoa, A.) (Taylor & Francis, 2003)."},{"key":"BFnrc1815_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.175.1.139","volume":"175","author":"S Singh","year":"1992","unstructured":"Singh, S. et al. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175, 139\u2013146 (1992).","journal-title":"J. Exp. Med."},{"key":"BFnrc1815_CR58","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.161.5.2099","volume":"161","author":"M Petersson","year":"1998","unstructured":"Petersson, M. et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1\/2 function in the prototype NK target YAC-1. J. Immunol. 161, 2099\u20132105 (1998).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00262-003-0443-2","volume":"53","author":"P Serafini","year":"2004","unstructured":"Serafini, P. et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53, 64\u201372 (2004).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrc1815_CR60","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","volume":"10","author":"B Vogelstein","year":"2004","unstructured":"Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789\u2013799 (2004).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR61","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137\u2013148 (2004).","journal-title":"Immunity"},{"key":"BFnrc1815_CR62","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nri1245","volume":"3","author":"JB Huppa","year":"2003","unstructured":"Huppa, J. B. & Davis, M. M. T-cell\u2013antigen recognition and the immunological synapse. Nature Rev. Immunol. 3, 973\u2013983 (2003).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrc1815_CR63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0065-230X(01)83005-0","volume":"83","author":"F Garrido","year":"2001","unstructured":"Garrido, F. & Algarra, I. MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res. 83, 117\u2013158 (2001).","journal-title":"Adv. Cancer Res."},{"key":"BFnrc1815_CR64","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00262-004-0517-9","volume":"53","author":"I Algarra","year":"2004","unstructured":"Algarra, I. et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 53, 904\u2013910 (2004). References 63 and 64 show that the loss of MHC-I expression by cancer cells is a frequent and important mechanism by which they avoid T-cell recognition.","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrc1815_CR65","first-page":"4119","volume":"63","author":"E Giorda","year":"2003","unstructured":"Giorda, E. et al. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Cancer Res. 63, 4119\u20134127 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","volume":"74","author":"FM Marincola","year":"2000","unstructured":"Marincola, F. M., Jaffee, E. M., Hicklin, D. J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181\u2013273 (2000).","journal-title":"Adv. Immunol."},{"key":"BFnrc1815_CR67","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1084\/jem.20031787","volume":"198","author":"OJ Finn","year":"2003","unstructured":"Finn, O. J. Premalignant lesions as targets for cancer vaccines. J. Exp. Med. 198, 1623\u20131626 (2003). An inspiring paper on the importance of finding new target antigens expressed by pre-malignant lesions.","journal-title":"J. Exp. Med."},{"key":"BFnrc1815_CR68","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1172\/JCI200317426","volume":"111","author":"C Curcio","year":"2003","unstructured":"Curcio, C. et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2\/neu carcinomas. J. Clin. Invest 111, 1161\u20131170 (2003). This paper shows that rejection of established rat ERBB2+ tumours does not rest on a single, dominant immune mechanism, but on a coordinated response involving CD4+and CD8+ T cells, antibodies, Fc receptors, CD1d-restricted NK T cells, macrophages, neutrophils, perforin and IFN\u03b3.","journal-title":"J. Clin. Invest"},{"key":"BFnrc1815_CR69","first-page":"2571","volume":"60","author":"G Forni","year":"2000","unstructured":"Forni, G., Lollini, P. L., Musiani, P. & Colombo, M. P. Immunoprevention of cancer: is the time ripe? Cancer Res. 60, 2571\u20132575 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR70","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/1097-0215(20000715)87:2<186::AID-IJC5>3.0.CO;2-1","volume":"87","author":"P Nanni","year":"2000","unstructured":"Nanni, P. et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer 87, 186\u2013194 (2000).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1815_CR71","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1535-6108(02)00212-X","volume":"2","author":"SE Moody","year":"2002","unstructured":"Moody, S. E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451\u2013461 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrc1815_CR72","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S1471-4906(02)00030-3","volume":"24","author":"PL Lollini","year":"2003","unstructured":"Lollini, P. L. & Forni, G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol. 24, 62\u201366 (2003).","journal-title":"Trends Immunol."},{"key":"BFnrc1815_CR73","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1200\/JCO.2002.06.171","volume":"20","author":"ML Disis","year":"2002","unstructured":"Disis, M. L. et al. Generation of T-cell immunity to the HER-2\/neu protein after active immunization with HER-2\/neu peptide-based vaccines. J. Clin. Oncol. 20, 2624\u20132632 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1815_CR74","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ijc.11497","volume":"108","author":"A Choudhury","year":"2004","unstructured":"Choudhury, A. et al. Small interfering RNA (siRNA) inhibits the expression of the Her2\/neu gene, upregulates HLA class I and induces apoptosis of Her2\/neu positive tumor cell lines. Int. J. Cancer 108, 71\u201377 (2004). This paper shows an inverse relationship between ERBB2 and HLA class I molecule expression.","journal-title":"Int. J. Cancer"},{"key":"BFnrc1815_CR75","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X","volume":"77","author":"PL Lollini","year":"1998","unstructured":"Lollini, P. L. et al. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2\/neu transgenic mice. Int. J. Cancer 77, 937\u2013941 (1998).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1815_CR76","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1038\/nm1220","volume":"11","author":"P Ritvo","year":"2005","unstructured":"Ritvo, P. et al. Vaccines in the public eye. Nature Med. 11, S20\u2013S24 (2005).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR77","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1046\/j.1523-1747.1998.00411.x","volume":"111","author":"T Okamoto","year":"1998","unstructured":"Okamoto, T. et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J. Invest Dermatol. 111, 1034\u20131039 (1998).","journal-title":"J. Invest Dermatol."},{"key":"BFnrc1815_CR78","doi-asserted-by":"crossref","unstructured":"Saha, A. et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol. Immunother. 1\u201313 (2005).","DOI":"10.1007\/s00262-005-0009-6"},{"key":"BFnrc1815_CR79","unstructured":"Novel Vaccination Strategies (ed. Kaufmann, S. H. E.) (Wiley-VCH, Weinheim, 2004)."},{"key":"BFnrc1815_CR80","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0065-230X(03)90005-4","volume":"90","author":"JA Guevara-Patino","year":"2003","unstructured":"Guevara-Patino, J. A., Turk, M. J., Wolchok, J. D. & Houghton, A. N. Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv. Cancer Res. 90, 157\u2013177 (2003).","journal-title":"Adv. Cancer Res."},{"key":"BFnrc1815_CR81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4049\/jimmunol.160.2.643","volume":"160","author":"DJ Morgan","year":"1998","unstructured":"Morgan, D. J. et al. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160, 643\u2013651 (1998).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/039463200501800217","volume":"18","author":"M Lo Iacono","year":"2005","unstructured":"Lo Iacono M. et al. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2\/NEU transgenic mice. Int. J. Immunopathol. Pharmacol. 18, 351\u2013363 (2005).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"BFnrc1815_CR83","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1038\/sj.onc.1202698","volume":"18","author":"FE Jones","year":"1999","unstructured":"Jones, F. E. & Stern, D. F. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 18, 3481\u20133490 (1999).","journal-title":"Oncogene"},{"key":"BFnrc1815_CR84","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/0008-5472.1071.65.3","volume":"65","author":"SM Pupa","year":"2005","unstructured":"Pupa, S. M. et al. Inhibition of mammary carcinoma development in HER-2\/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res. 65, 1071\u20131078 (2005).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR85","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nm0696-622","volume":"2","author":"AR Jonsen","year":"1996","unstructured":"Jonsen, A. R., Durfy, S. J., Burke, W. & Motulsky, A. G. The advent of the 'unpatients'. Nature Med. 2, 622\u2013624 (1996).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR86","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature03727","volume":"435","author":"M Feldmann","year":"2005","unstructured":"Feldmann, M. & Steinman, L. Design of effective immunotherapy for human autoimmunity. Nature 435, 612\u2013619 (2005).","journal-title":"Nature"},{"key":"BFnrc1815_CR87","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ejca.2003.11.021","volume":"40","author":"MC Bibby","year":"2004","unstructured":"Bibby, M. C. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur. J. Cancer 40, 852\u2013857 (2004).","journal-title":"Eur. J. Cancer"},{"key":"BFnrc1815_CR88","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrd1635","volume":"4","author":"A Kamb","year":"2005","unstructured":"Kamb, A. What's wrong with our cancer models? Nature Rev. Drug Discov. 4, 161\u2013165 (2005).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc1815_CR89","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1517\/14712598.5.5.717","volume":"5","author":"F Cavallo","year":"2005","unstructured":"Cavallo, F., Curcio, C. & Forni, G. Immunotherapy and immunoprevention of cancer: where do we stand? Expert Opin. Biol. Ther. 5, 717\u2013726 (2005).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFnrc1815_CR90","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/1568009053765762","volume":"5","author":"PL Lollini","year":"2005","unstructured":"Lollini, P. L. et al. New target antigens for cancer immunoprevention. Curr. Cancer Drug Targets 5, 221\u2013228 (2005).","journal-title":"Curr. Cancer Drug Targets"},{"key":"BFnrc1815_CR91","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127\u2013137 (2001).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrc1815_CR92","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.4049\/jimmunol.173.7.4699","volume":"173","author":"WK Bleeker","year":"2004","unstructured":"Bleeker, W. K. et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173, 4699\u20134707 (2004).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR93","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/0470869976.ch6","volume":"262","author":"MN Pollak","year":"2004","unstructured":"Pollak, M. N. Insulin-like growth factors and neoplasia. Novartis Found. Symp. 262, 84\u201398 (2004).","journal-title":"Novartis Found. Symp."},{"key":"BFnrc1815_CR94","doi-asserted-by":"publisher","first-page":"E877","DOI":"10.1152\/ajpendo.2001.280.6.E877","volume":"280","author":"MJ Fedele","year":"2001","unstructured":"Fedele, M. J., Lang, C. H. & Farrell, P. A. Immunization against IGF-I prevents increases in protein synthesis in diabetic rats after resistance exercise. Am. J. Physiol. Endocrinol. Metab. 280, E877\u2013E885 (2001).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrc1815_CR95","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/08916930400001909","volume":"37","author":"K Kodama","year":"2004","unstructured":"Kodama, K. et al. Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice. Autoimmunity 37, 481\u2013487 (2004).","journal-title":"Autoimmunity"},{"key":"BFnrc1815_CR96","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1535-6108(02)00208-8","volume":"2","author":"S Rafii","year":"2002","unstructured":"Rafii, S. Vaccination against tumor neovascularization: promise and reality. Cancer Cell 2, 429\u2013431 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrc1815_CR97","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.V94.2.673","volume":"94","author":"M Massaia","year":"1999","unstructured":"Massaia, M. et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94, 673\u2013683 (1999).","journal-title":"Blood"},{"key":"BFnrc1815_CR98","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","volume":"99","author":"JM Timmerman","year":"2002","unstructured":"Timmerman, J. M. et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517\u20131526 (2002).","journal-title":"Blood"},{"key":"BFnrc1815_CR99","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/nm1204-1279a","volume":"10","author":"JM Timmerman","year":"2004","unstructured":"Timmerman, J. M. & Levy, R. Correspondence 2: cancer vaccines: pessimism in check. Nature Med. 10, 1279 (2004).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR100","first-page":"3569","volume":"60","author":"RT Reilly","year":"2000","unstructured":"Reilly, R. T. et al. HER-2\/neu is a tumor rejection target in tolerized HER-2\/neu transgenic mice. Cancer Res. 60, 3569\u20133576 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR101","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s002620050519","volume":"47","author":"A Amici","year":"1998","unstructured":"Amici, A., Venanzi, F. M. & Concetti, A. Genetic immunization against neu\/erbB2 transgenic breast cancer. Cancer Immunol. Immunother. 47, 183\u2013190 (1998).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrc1815_CR102","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1158\/0008-5472.CAN-05-0335","volume":"65","author":"K Tegerstedt","year":"2005","unstructured":"Tegerstedt, K. et al. A single vaccination with polyomavirus VP1\/VP2Her2 virus-like particles prevents outgrowth of HER-2\/neu-expressing tumors. Cancer Res. 65, 5953\u20135957 (2005).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR103","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942\u2013949 (2004).","journal-title":"Nature Med."},{"key":"BFnrc1815_CR104","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood-2003-01-0190","volume":"102","author":"C Melani","year":"2003","unstructured":"Melani, C., Chiodoni, C., Forni, G. & Colombo, M. P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB\/c mice suppresses immune reactivity. Blood 102, 2138\u20132145 (2003).","journal-title":"Blood"},{"key":"BFnrc1815_CR105","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1084\/jem.194.6.823","volume":"194","author":"RP Sutmuller","year":"2001","unstructured":"Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823\u2013832 (2001).","journal-title":"J. Exp. Med."},{"key":"BFnrc1815_CR106","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1172\/JCI17323","volume":"113","author":"T Iinuma","year":"2004","unstructured":"Iinuma, T. et al. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest 113, 1307\u20131317 (2004).","journal-title":"J. Clin. Invest"},{"key":"BFnrc1815_CR107","first-page":"6944","volume":"62","author":"JW Greiner","year":"2002","unstructured":"Greiner, J. W., Zeytin, H., Anver, M. R. & Schlom, J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62, 6944\u20136951 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR108","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1158\/0008-5472.CAN-03-3878","volume":"64","author":"HE Zeytin","year":"2004","unstructured":"Zeytin, H. E. et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg\/MIN mice. Cancer Res. 64, 3668\u20133678 (2004).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR109","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ijc.21349","volume":"118","author":"J Steitz","year":"2006","unstructured":"Steitz, J. et al. Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. Int. J. Cancer 118, 373\u2013380 (2006).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1815_CR110","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/eji.200425531","volume":"35","author":"E Degl'Innocenti","year":"2005","unstructured":"Degl'Innocenti, E. et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 35, 66\u201375 (2005).","journal-title":"Eur. J. Immunol."},{"key":"BFnrc1815_CR111","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.4049\/jimmunol.170.4.1980","volume":"170","author":"J Xia","year":"2003","unstructured":"Xia, J. et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic\/tumor fusion cells. J. Immunol. 170, 1980\u20131986 (2003).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR112","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s002620050539","volume":"47","author":"LJ Esserman","year":"1999","unstructured":"Esserman, L. J. et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother. 47, 337\u2013342 (1999).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrc1815_CR113","first-page":"3782","volume":"60","author":"NK Dakappagari","year":"2000","unstructured":"Dakappagari, N. K. et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60, 3782\u20133789 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc1815_CR114","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.4049\/jimmunol.171.8.4054","volume":"171","author":"MH Manjili","year":"2003","unstructured":"Manjili, M. H. et al. HSP110-HER2\/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2\/neu transgenic mice. J. Immunol. 171, 4054\u20134061 (2003).","journal-title":"J. Immunol."},{"key":"BFnrc1815_CR115","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<393::AID-IJC16>3.0.CO;2-M","volume":"83","author":"D Cefai","year":"1999","unstructured":"Cefai, D. et al. Targeting HER-2\/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int. J. Cancer 83, 393\u2013400 (1999).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1815_CR116","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1186\/bcr962","volume":"7","author":"X Wang","year":"2005","unstructured":"Wang, X., Wang, J. P., Maughan, M. F. & Lachman, L. B. Alphavirus replicon particles containing the gene for HER2\/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res. 7, R145\u2013R155 (2005).","journal-title":"Breast Cancer Res."},{"key":"BFnrc1815_CR117","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nrc841","volume":"2","author":"S Stevanovic","year":"2002","unstructured":"Stevanovic, S. Identification of tumour-associated T-cell epitopes for vaccine development. Nature Rev. Cancer 2, 514\u2013520 (2002).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1815_CR118","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nm0598-627","volume":"4","author":"Z Qin","year":"1998","unstructured":"Qin, Z. et al. B cells inhibit induction of T cell-dependent tumor immunity. Nature Med. 4, 627\u2013630 (1998).","journal-title":"Nature Med."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrc1815","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrc1815.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrc1815.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T02:58:49Z","timestamp":1706929129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc1815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3,1]]}},"alternative-id":["BFnrc1815"],"URL":"https:\/\/doi.org\/10.1038\/nrc1815","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,1]]},"assertion":[{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}